EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bridging Discovery and Treatment: Cancer Biomarker

Hengrui Liu iD, Ilayda Karsidag, Rebecca Golin, Guangzhen Wu iD

Cancers · 20.11.2025 · 17 (22) · 3720

DOI: 10.3390/cancers17223720 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.11.2025. Verfasst von Hengrui Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers have transformed cancer care by linking molecular insights to personalized treatment strategies. This review first surveys the spectrum of detection modalities, including tissue genomics and histopathology; liquid biopsies such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles; imaging and radiomics; and multi-omic approaches spanning epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics. We then critically appraise the translational challenges that hinder clinical implementation, assay standardization, data integration, analytical and clinical validation, regulatory pathways, and cost-effectiveness. Finally, we explore emerging solutions, including artificial intelligence (AI)-driven multi-modal phenotyping, adaptive trial designs, and point-of-care assays, and outline future directions for expanding access and equitable adoption. By emphasizing the central role of biomarkers in guiding targeted and immune-based therapies, we underscore their potential to overcome tumor heterogeneity, preempt resistance, and ultimately improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

cancer biomarkersmulti-omics technologiespersonalized medicineprecision oncologytranslational researchtumor heterogeneity

Autor:innen und Institutionen

  • Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.
  • School of Biological Sciences, University of California San Diego, San Diego, CA 92093, USA.
  • Leon M Goldstein School, New York, NY 11235, USA.
  • Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.

ORCID-Profile: Hengrui Liu, Guangzhen Wu

Zitieren

APA

Liu, H., Karsidag, I., Golin, R., & Wu, G. (2025). Bridging Discovery and Treatment: Cancer Biomarker. Cancers, 17(22), 3720. https://doi.org/10.3390/cancers17223720

Vancouver

Liu H, Karsidag I, Golin R, Wu G. Bridging Discovery and Treatment: Cancer Biomarker. Cancers. 2025;17(22):3720. doi:10.3390/cancers17223720

BibTeX
@article{Liu2025,
  author = {Liu, Hengrui and Karsidag, Ilayda and Golin, Rebecca and Wu, Guangzhen},
  title = {Bridging Discovery and Treatment: Cancer Biomarker},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {22},
  pages = {3720},
  doi = {10.3390/cancers17223720}
}
Kostenlos starten →